Asako Harada - Concepedia

Author

Asako Harada

Chugai Pharma (United States)

Also Known As

Asako Harada

Publications

411

Citations

H-Index

Concepts

All Affiliations

Chugai Pharma (United States)

About

Asako Harada is an author at Chugai Pharma (United States) specializing in medicine, molecular biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	113
2	Cell Biology	2	2	34
3	Engineering	1	1	44
4	Allergy	1	1	44
5	Cellular Physiology	1	1	12

Asako Harada

Publications

331

Citations

H-Index

Page 1

	Year	Citations
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors Takahiro Ishiguro, Yuji Sano, Shunichiro Komatsu, Science Translational Medicine	2017	195
Whole cell-ELISA to measure the γH2AX response of six aneugens and eight DNA-damaging chemicals Kaori Matsuzaki, Asako Harada, Akira Takeiri, Mutation Research/Genetic Toxicology and Environmental Mutagenesis γH2ax ResponseEngineeringAllergyMedicineBioanalysis	2010	44
Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy Michio Hoshi, Asako Harada, Takeshi Kawase, Cancer Gene Therapy Metalloproteinases-2 GeneImmunologyTissue InhibitorTumor TargetingAnti-cancer Agent	2000	24
High-content imaging analyses of γH2AX-foci and micronuclei in TK6 cells elucidated genotoxicity of chemicals and their clastogenic/aneugenic mode of action Akira Takeiri, Kaori Matsuzaki, Shigeki Motoyama, Genes and Environment	2019	23
The predominant role of apoptosis in γH2AX formation induced by aneugens is useful for distinguishing aneugens from clastogens Asako Harada, Kaori Matsuzaki, Akira Takeiri, Mutation Research/Genetic Toxicology and Environmental Mutagenesis MedicinePredominant RoleApoptosisγH2ax FormationCell Death	2014	22
A newly established GDL1 cell line from gpt delta mice well reflects the in vivo mutation spectra induced by mitomycin C Akira Takeiri, Masayuki Mishima, Kenji Tanaka, Mutation Research/Genetic Toxicology and Environmental Mutagenesis Genome InstabilityMitomycin CMolecular BiologyCell CycleMedicine	2006	12
Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy Yoshika Iwata, Masanori Sasaki, Asako Harada, Toxicology and Applied Pharmacology Cancer ImmunosurveillanceCynomolgus MonkeysBispecific Antibody Ery974ImmunologyTumor Immunity	2019	11

Page 1